Winslow Asset Management Inc. Has $319,000 Position in Pfizer Inc. (NYSE:PFE)

Winslow Asset Management Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 14.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,085 shares of the biopharmaceutical company’s stock after selling 1,820 shares during the quarter. Winslow Asset Management Inc.’s holdings in Pfizer were worth $319,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. GoalVest Advisory LLC boosted its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. VisionPoint Advisory Group LLC boosted its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the 4th quarter valued at $36,000. DiNuzzo Private Wealth Inc. bought a new position in shares of Pfizer in the 4th quarter valued at $37,000. Finally, Life Planning Partners Inc bought a new position in shares of Pfizer in the 4th quarter valued at $39,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PFE. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $35.86.

Get Our Latest Stock Report on PFE

Pfizer Price Performance

Shares of Pfizer stock traded down $0.05 during trading on Friday, hitting $27.60. The stock had a trading volume of 17,766,140 shares, compared to its average volume of 41,409,297. The firm has a market cap of $156.40 billion, a price-to-earnings ratio of -459.42, a P/E/G ratio of 1.09 and a beta of 0.70. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.36. The business’s 50-day moving average is $27.55 and its 200 day moving average is $27.81. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.23 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.09%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.